Lorenzo Marcucci

Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer

Gianluca Masi, Samanta Cupini, Lorenzo Marcucci et al. · Annals of Surgical Oncology · 2005 · 162 citations

Surgical Oncology, 5-Fluorouracil/folinic Acid, Colorectal Surgery +6

FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.

Alfredo Falcone, Chiara Cremolini, Gianluca Masi et al. · Journal of Clinical Oncology · 2013 · 75 citations

Pathology, Gono Group, First-line Treatment +16

FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · Journal of Clinical Oncology · 2013 · 37 citations

Pathology, Pharmacotherapy, Tribe Trial +16

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial

Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro et al. · European Journal of Cancer · 2019 · 36 citations · Full text

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +8

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer

Gianluca Masi, Lorenzo Marcucci, Fotios Loupakis et al. · Annals of Oncology · 2006 · 23 citations · Full text

Oncology, Second Line Treatments, Medicine +7